Interplay between CRP, Atherogenic LDL, And LOX-1 and its potential role in the pathogenesis of atherosclerosis

Clinical Chemistry

Volumn 62, Issue 2, 2016, Pages 320-327

  Stancel, Nicole ^a   Chen, Chih Chieh ^b,c   Ke, Liang Yin ^b,d   Chu, Chih Sheng ^b,d   Lu, Jonathan ^a   Sawamura, Tatsuya ^a,e   Chen, Chu Huang ^a,b,d,f,g,h  

^a TEXAS HEART INSTITUTE   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h New York Heart Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHATIDYLCHOLINE; PHOSPHORYLCHOLINE; SERUM AMYLOID P; LOW-DENSITY LIPOPROTEIN L5, HUMAN; OLR1 PROTEIN, HUMAN;

ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; LIGAND BINDING; MACROPHAGE; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; AORTA; BLOOD; CHEMISTRY; METABOLISM; VASCULAR ENDOTHELIUM;

AORTA; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; SCAVENGER RECEPTORS, CLASS E;

EID: 84957101712     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.243923     Document Type: Review

References (45)

1. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557- 65.
2. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2010;56:e50 -103.
3. Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 2009;55:285-94.
4. Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE. Topology and structure of the C1q-binding site on C-reactive protein. J Immunol 2001;166:3998 - 4004.
5. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002;99:13043- 8.
6. Fujita Y, Kakino A, Harada-Shiba M, Sato Y, Otsui K, Yoshimoto R, Sawamura T. C-reactive protein uptake by macrophage cell line via class-A scavenger receptor. Clin Chem 2010;56:478 - 81.
7. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005;25:1359 - 63.
8. Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive proteininduced endothelial dysfunction. Circ Res 2004;95: 877- 83.
9. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52:561-71.
10. McCarty M. The occurrence during acute infections of a protein not normally present in the blood: IV. Crystallization of the C-reactive protein. J Exp Med 1947;85: 491- 8.
11. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 2008;456: 989 -92.
12. Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, Volanakis JE, et al. Three dimensional structure of human C-reactive protein. Nat Struct Biol 1996;3:346 - 54.
13. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974;112: 2135- 47.
14. Volanakis JE, Kaplan MH. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med 1971;136: 612- 4.
15. Thiele JR, Habersberger J, Braig D, Schmidt Y, Goerendt K, Maurer V, et al. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation 2014;130:35-50.
16. Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006;296:2703-11.
17. Torzewski M, Waqar AB, Fan J. Animal models of C-reactive protein. Mediators Inflamm 2014:683598, 2014.
18. Dunn S, Vohra RS, Murphy JE, Homer-Vanniasinkam S, Walker JH, Ponnambalam S. The lectin-like oxidized low-density-lipoprotein receptor: A pro-inflammatory factor in vascular disease. Biochem J 2008;409:349 - 55.
19. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386: 73-7.
20. Park H, Adsit FG, Boyington JC. The 1.4 angstrom crystal structure of the human oxidized low density lipoprotein receptor lox-1. J Biol Chem 2005;280:13593-9.
21. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 2000;20:1116 -22.
22. Lu J, Yang JH, Burns AR, Chen HH, Tang D, Walterscheid JP, et al. Mediation of electronegative low-density lipoprotein signaling by LOX-1: A possible mechanism of endothelial apoptosis. Circ Res 2009;104:619 -27.
23. Chen CH, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003;107:2102- 8.
24. Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, Chen HH, et al. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 2008;57:158 - 66.
25. Tang D, Lu J, Walterscheid JP, Chen HH, Engler DA, Sawamura T, et al. Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res 2008;49:33- 47.
26. Chan HC, Ke LY, Chu CS, Lee AS, Shen MY, Cruz MA, et al. Highly electronegative LDL from patients with STelevation myocardial infarction triggers platelet activation and aggregation. Blood 2013;122:3632- 41.
27. Itabe H, Ueda M. Measurement of plasma oxidized lowdensity lipoprotein and its clinical implications. J Atheroscler Thromb 2007;14:1-11.
28. Inoue N, Okamura T, Kokubo Y, Fujita Y, Sato Y, Nakanishi M, et al. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem 2010;56:550 - 8.
29. Hsu JF, Chou TC, Lu J, Chen SH, Chen FY, Chen CC, et al. Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor. PLoS One 2014;9:e107340.
30. Hein TW, Qamirani E, Ren Y, Xu X, Thengchaisri N, Kuo L. Selective activation of lectin-like oxidized low-density lipoprotein receptor-1 mediates C-reactive proteinevoked endothelial vasodilator dysfunction in coronary arterioles. Circ Res 2014;114:92-100.
31. Fujita Y, Yamaguchi S, Kakino A, Iwamoto S, Yoshimoto R, Sawamura T. Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation. Clin Chem 2011;57:1398 - 405.
32. Tsai MH, Chang CL, Yu YS, Lin TY, Chong CP, Lin YS, et al. Chemical analysis of C-reactive protein synthesized by human aortic endothelial cells under oxidative stress. Anal Chem 2012;84:9646 -54.
33. Chu CS, Wang YC, Lu LS, Walton B, Yilmaz HR, Huang RY, et al. Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS One 2013;8:e70533.
34. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158: 1039 -51.
35. Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 2003;23:1398 - 404.
36. Sattler KJ, Woodrum JE, Galili O, Olson M, Samee S, Meyer FB, et al. Concurrent treatment with reninangiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques. Stroke 2005;36:14 -20.
37. Forte L, Cimmino G, Loffredo F, De Palma R, Abbate G, Calabro P, et al. C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. Int J Cardiol 2011;152:7-12.
38. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 2005;166: 1265-71.
39. Meuwissen M, van der Wal AC, Niessen HW, Koch KT, de Winter RJ, van der Loos CM, et al. Colocalisation of intraplaque C reactive protein, complement, oxidized low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol 2006;59:196 -201.
40. Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 2007;14:3209 -20.
41. Chang MK, Hartvigsen K, Ryu J, Kim Y, Han KH. The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine. J Inflamm (Lond) 2012;9:42.
42. Estruch M, Sanchez-Quesada JL, Ordonez Llanos J, Benitez S. Electronegative LDL: A circulating modified LDL with a role in inflammation. Mediators Inflamm 2013;2013:181324.
43. van Tits L, de Graaf J, Toenhake H, van Heerde W, Stalenhoef A. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 2005;25:717-22.
44. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008;49:1015-23.
45. Wang HW, Sui SF. Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochem Biophys Res Commun 2001;288:75-9.